Correction to: Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial.

Following publication of the original article [1], the authors notified us o that the Table 1 citation within the legend was not presented as initially requested.

RCT Entities:   Population Interventions Outcomes

Correction

Following publication of the original article [1], the authors notified us that the citation within the Table 1 legend was not presented as initially requested. Also, the word “efficacy” was missed from the background section.

The original publication has been corrected. The incorrect and correct table citations as well as background information are presented below.

Originally published citation:

© 2018 Tassorelli C, Grazzi L, de Tommaso M, Pierangeli G, Martelletti P, Rainero I, Dorlas S, Geppetti P, Ambrosini A, Sarchielli P, Liebler E, Barbanti P, PRESTO Study Group (2018) Non-invasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study [published online June 15, 2018]. Neurology: 10.1212/WNL.0000000000005857. www.neurology.org. Adapted with permission

Abbreviations: DB Double-blind, NA Not applicable, nVNS Non-invasive vagus nerve stimulation, SD Standard deviation

aNo. of days the patient typically takes acute migraine medication per month. bPatients with no reported baseline severity were excluded from this analysis

Corrected citation:

© 2018 Tassorelli C, Grazzi L, de Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91(4):e364-e373. Adapted with permission

Original Background paragraph:

Opioids should be discouraged for the acute treatment of migraine due to significant safety concerns and lack of documented but remain frequently used in the emergency department setting, which significantly increases healthcare costs

Corrected Background paragraph:

Opioids should be discouraged for the acute treatment of migraine due to significant safety concerns and lack of documented efficacy but remain frequently used in the emergency department setting, which significantly increases healthcare costs